PACS1-targeted antisense oligonucleotide
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PACS1-targeted antisense oligonucleotide, covering 2026-03-16 to 2026-03-16. Get the full timeline:
Most recent: Clinical Trial Update: Personalized Antisense Oligonucleotide for A Single Participant With PACS1 Gene Mutation Associated With Schuurs-Hoeijmakers Syndrome (SHMS) [Phase 1, Phase 2]